Muge Kesen, MD
Retina Specialist · Mc Lean, VANPI 1770676017
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $19,160 of the $29,822 with a category attached, or 64.2%. 23 manufacturers reported payments, led by Genentech USA, Inc. at 57.1% of the total. Among retina specialist clinicians in VA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $432.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$17K
- AbbVie$6K
- Regeneron$4K
- Mallinckrodt Hospital Products Inc.$477
- Genentech, Inc.$399
- Alcon$245
- plus $2K from 17 others
What the payments were for
- Consulting fees$19,16064%
- Speaking & faculty fees$4,75016%
- Travel & lodging$1,8326%
- Food & beverage$3,90413%
- Education$850%
- Entertainment$910%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 17 | $17,030 |
| AbbVie(2 entities) | 10 | $6,427 |
| Regeneron | 3 | $3,567 |
| Mallinckrodt Hospital Products Inc. | 7 | $477 |
| Genentech, Inc. | 4 | $399 |
| Alcon | 3 | $245 |
| Alimera Sciences, Inc. | 1 | $173 |
| Rxsight Inc | 2 | $151 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $147 |
| Coopervision Inc. | 1 | $143 |
| Biotissue Holdings Inc. | 1 | $137 |
| Regeneron Healthcare Solutions, Inc. | 5 | $134 |
| Amgen | 1 | $125 |
| Dompe US, Inc. | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 1 | $95 |
| Optos, Inc. | 1 | $91 |
| Iridex Corporation | 2 | $78 |
| Astellas Pharma Global Development | 1 | $72 |
| Topcon Healthcare, Inc. | 1 | $70 |
| Coherus Oncology, Inc. | 2 | $56 |
| Apellis Pharmaceuticals, Inc. | 2 | $39 |
| GSK | 1 | $21 |
| Eyepoint US, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$4,750
- EYLEA$3,475
- VABYSMO$380
- ACTHAR$279
- YUTIQ$173
- VITESSE$147
- STELLARIS PC$147
- MiSight Contact Lens$143
- Prokera$137
- TEPEZZA$125
- Oxervate$125
- XEN GLAUCOMA TREATMENT SYSTEM$114
- Clareon$111
How this compares
$29,822 in reported general payments places this provider in the 90th percentile of 41 retina specialist providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 18 | $9,323 |
| Bromfenac Sodium | 37 | $5,086 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $2,700 |
| Prednisolone Acetate | 53 | $2,460 |
| Ketorolac Tromethamine | 71 | $2,029 |
| Difluprednate | 20 | $1,709 |
| Dorzolamide Hcl | 12 | $177 |
| ErythromycinErythromycin Base | 15 | $156 |
| Timolol Maleate | 13 | $150 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 11 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $147 | $9,32318 claims |
| AlconSimbrinza | $245 | $2,70015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 41 retina specialist providers in Virginia.
Other retina specialist in Mc Lean
- Jordana FeinManassas$412K
- Joaquin TosiVirginia Beach$48K
- Mohit NandaCharlottesville$31K
- Anna MackinRoanoke$26K
- Jon AdlebergChesapeake$21K
- Dal ChunVienna$12K
- Kori ElkinsPortsmouth$9K
- Jiwei ShengFairfax$8K
- Timothy ByrnesRoanoke$7K
- Alexander MelamudFairfax$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.